{"id":"iptp-sulphadoxine-pyrimethamine-plus-metronidazole","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbance"},{"rate":null,"effect":"Metallic taste (metronidazole)"},{"rate":null,"effect":"Allergic reactions (sulphonamide sensitivity)"},{"rate":null,"effect":"Peripheral neuropathy (rare)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sulphadoxine-pyrimethamine (SP) is an antifolate combination that inhibits plasmodial dihydrofolate reductase, preventing malaria parasites from synthesizing nucleotides. Metronidazole is a nitroimidazole that disrupts bacterial and parasitic DNA, providing additional coverage against anaerobic bacteria and protozoa. IPTp (intermittent preventive treatment in pregnancy) uses this combination to reduce malaria infection and associated adverse pregnancy outcomes.","oneSentence":"This combination therapy prevents malaria and treats bacterial/parasitic infections in pregnant women through antifolate antimalarial activity and broad-spectrum antimicrobial action.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:48:49.029Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Malaria prevention in pregnant women (intermittent preventive treatment)"},{"name":"Reduction of adverse pregnancy outcomes associated with malaria infection"}]},"trialDetails":[{"nctId":"NCT04189744","phase":"PHASE3","title":"The ASPIRE Trial - Aiming for Safe Pregnancies by Reducing Malaria and Infections of the Reproductive Tract","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2019-12-15","conditions":"Pregnancy Malaria, Bacterial Vaginoses, Trichomonas Vaginitis","enrollment":5436},{"nctId":"NCT03079388","phase":"NA","title":"Nutritional and Anti-infective Interventions for Malnutrition in Pregnancy (Beleuman Welbodi)","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2017-02-27","conditions":"Pregnancy, Malnutrition in Pregnancy, Nutrition Disorders","enrollment":1489}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Fansidar","Flagyl"],"phase":"phase_3","status":"active","brandName":"IPTp-sulphadoxine-pyrimethamine plus metronidazole","genericName":"IPTp-sulphadoxine-pyrimethamine plus metronidazole","companyName":"London School of Hygiene and Tropical Medicine","companyId":"london-school-of-hygiene-and-tropical-medicine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination therapy prevents malaria and treats bacterial/parasitic infections in pregnant women through antifolate antimalarial activity and broad-spectrum antimicrobial action. Used for Malaria prevention in pregnant women (intermittent preventive treatment), Reduction of adverse pregnancy outcomes associated with malaria infection.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}